Translations:Discovery and development of angiotensin receptor blockers/35/en

From Azupedia
Jump to navigation Jump to search

Olmesartan medoxomil was developed by Sankyo in 1995 and is the newest ARB on the market, marketed in 2002. It is an ester prodrug like candesartan cilexetil. In vivo, the prodrug is completely and rapidly hydrolyzed to the active acid form, olmesartan (RNH-6270). It has a hydroxyisopropyl group connected to the imidazole ring in addition to the carboxyl group.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Discovery_and_development_of_angiotensin_receptor_blockers/35/en&oldid=131492"